Co-Diagnostics, Inc.
CODXHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Co-Diagnostics, Inc. focuses on Medical Devices services and products. Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in. At a $8.6M market cap, Co-Diagnostics, Inc. ranks as a micro-cap company within healthcare. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.
Market Cap
$8.6M
Beta
2.85
P/E (TTM)
—
P/E (Fwd)
-0.20
EPS (TTM)
$-30.59
EPS (Fwd)
$-12.00
ROE
-151.7%
ROA
-52.1%
Cash
$8.2M
Total Debt
$2.0M
Free CF
-$18.3M
52W Change
-73.2%
Annual Financials
Cash vs Debt
Where CODX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CODX finished 28.81% below its 150-day moving average ($3.61) and 54.59% below its 200-day moving average ($5.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CODX overbought or oversold?
At the July 15, 2026 close, CODX's RSI(14) was 29.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Co-Diagnostics, Inc. holds $8.2M in cash against $2.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$18.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -151.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $97.9M (2021) to $622K (2025), a 99% decline worth watching.
A beta of 2.85 means CODX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CODX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Co-Diagnostics, Inc. and its sector.